^
Association details:
| Biomarker: | MET overexpression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + Tafinlar (dabrafenib) (BRAF inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Whole exome and transcriptome sequencing of colorectal and pancreatic cancer.
Published date:
05/28/2020
Excerpt:
A 55 year-old met pt with PC was treated with standard chemotherapy. Upon disease progression pt was sequenced and based on presence of BRAF V600E, pt was treated with trametinib and dabrafenib. Following disease progression on BRAF/MEKi, met sample was resequenced and RNA expression analysis found increased expression of MET, MACC1 and SMAD7 and 4-fold decrease in PTEN which could potentially cause resistance to BRAF/MEKi therapy.
DOI:
10.1200/JCO.2020.38.15_suppl.e15666
